Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/208466
Title: | The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases |
Author: | Navarro Compán, Victoria Puig, Luis Vidal, Silvia Ramírez, Julio Llamas Velasco, Mar Fernández Carballido, Cristina Almodóvar, Raquel Pinto, José Antonio Galíndez Aguirregoikoa, Eva Zarco, Pedro Joven, Beatriz Gratacós, Jordi Juanola, Xavier Blanco, Ricardo Arias Santiago, Salvador Sanz Sanz, Jesús Queiro, Rubén Cañete, Juan D. |
Keywords: | Malalties cròniques Limfòcits Psoriasi Chronic Disease Lymphocytes Psoriasis |
Issue Date: | 4-Aug-2023 |
Publisher: | Frontiers Media SA |
Abstract: | Interleukin-17 family (IL-17s) comprises six structurally related members (IL-17A to IL-17F); sequence homology is highest between IL-17A and IL-17F, displaying certain overlapping functions. In general, IL-17A and IL-17F play important roles in chronic inflammation and autoimmunity, controlling bacterial and fungal infections, and signaling mainly through activation of the nuclear factor-kappa B (NF-kappa B) pathway. The role of IL-17A and IL-17F has been established in chronic immune-mediated inflammatory diseases (IMIDs), such as psoriasis (PsO), psoriatic arthritis (PsA), axial spondylarthritis (axSpA), hidradenitis suppurativa (HS), inflammatory bowel disease (IBD), multiple sclerosis (MS), and asthma. CD4(+) helper T cells (Th17) activated by IL-23 are well-studied sources of IL-17A and IL-17F. However, other cellular subtypes can also produce IL-17A and IL-17F, including gamma delta (gamma delta) T cells, alpha beta (alpha beta) T cells, type 3 innate lymphoid cells (ILC3), natural killer T cells (NKT), or mucosal associated invariant T cells (MAIT). Interestingly, the production of IL-17A and IL-17F by innate and innate-like lymphocytes can take place in an IL-23 independent manner in addition to IL-23 classical pathway. This would explain the limitations of the inhibition of IL-23 in the treatment of patients with certain rheumatic immune-mediated conditions such as axSpA. Despite their coincident functions, IL-17A and IL-17F contribute independently to chronic tissue inflammation having somehow non-redundant roles. Although IL-17A has been more widely studied, both IL-17A and IL-17F are overexpressed in PsO, PsA, axSpA and HS. Therefore, dual inhibition of IL-17A and IL-17F could provide better outcomes than IL-23 or IL-17A blockade. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2023.1191782 |
It is part of: | Frontiers in Immunology, 2023, vol. 14 |
URI: | http://hdl.handle.net/2445/208466 |
Related resource: | https://doi.org/10.3389/fimmu.2023.1191782 |
ISSN: | 1664-3224 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-14-1191782.pdf | 4.26 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License